Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Link-Asia International MedTech Group Limited

環 亞 國 際 醫 療 科 技 集 團 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

COMPLETION OF ASSIGNMENT OF AGENCY AGREEMENT INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER THE SPECIFIC MANDATE

Reference is made to the announcement dated 18 January 2022 and the circular dated 13 May 2022 (the "**Circular**") of Link-Asia International MedTech Group Limited (the "**Company**"), in respect of the Discloseable Transaction in relation to the Assignment of Agency Agreement involving the Issue of Consideration Shares under Specific Mandate. Unless otherwise defined herein, any terms used in this announcement shall have the same meanings as those defined in the Circular.

THE ASSIGNMENT

On 18 January 2022, the Assignee, the Company and the Assignor entered into the Deed of Assignment, pursuant to which the Assignee agreed to accept and the Assignor agreed to assign all its rights, obligations, title, interest, and benefit in and to the Agency Agreement to the Assignee. The Consideration for the Assignment is HK\$37,800,000, which shall be settled by the allotment and issue of 230,000,000 Consideration Shares to the Assignor (or its nominee) upon Completion.

COMPLETION OF THE ASSIGNMENT

The Board is pleased to announce that all conditions precedent in respect of the Assignment as set out in the sub-section headed "THE DEED OF ASSIGNMENT — Conditions precedent" on page 15 of the Circular have been fulfilled and the Completion took place on 10 June 2022. Upon Completion, the Assignor has become a substantial shareholder (as defined under the Listing Rules) of the Company.

ISSUE OF CONSIDERATION SHARES UNDER THE SPECIFIC MANDATE AND CHANGES IN SHAREHOLDING STRUCTURE

Immediately before the Completion, the Company had 924,363,855 Shares in issue. Upon Completion, 230,000,000 new Shares, representing approximately 19.92% of the issued share capital of the Company as at the date of this announcement (as enlarged by the issue of the Consideration Shares), have been duly allotted and issued as fully paid to the Assignor at the issue price of HK\$0.164 per Consideration Share under the Specific Mandate granted by Shareholders at the EGM held on 31 May 2022. Accordingly, immediately after the Completion, there are 1,154,363,855 Shares in issue.

Set out below for illustrative purposes is the shareholding structure of the Company (i) immediately before Completion; and (ii) immediately upon Completion:

	Immediately before Completion		Immediately upon Completion	
	No. of Shares	%	No. of Shares	%
Power Port Holdings Limited (Note 1)	75,817,000	8.20	75,817,000	6.57
Keywan Global Limited (<i>Note 2</i>) Assignor	49,500,000	5.36	49,500,000 230,000,000	4.29 19.92
Public Shareholders	799,046,855	86.44	799,046.855	69.22
Total	924,363,855	100.00	1,154.363,855	100.00

Notes:

- 1. Power Port Holdings Limited, which is a company incorporated in the British Virgin Islands, is whollyowned by Ms. Yang Changrong.
- 2. Keywan Global Limited, which is a company incorporated in the British Virgin Islands, is wholly-owned by Mr. He Xiaoming.
- 3. The percentage figures have been subject to rounding adjustments. Any discrepancies between totals and sums of amounts listed herein are due to rounding adjustments.

By order of the Board Link-Asia International MedTech Group Limited Lin Dailian

Chairman and executive Director

Hong Kong, 10 June 2022

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.